Vertex Pharmaceuticals (VRTX) Receiving Somewhat Favorable News Coverage, Report Finds
News headlines about Vertex Pharmaceuticals (NASDAQ:VRTX) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the pharmaceutical company an impact score of 45.6645334013521 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern’s analysis:
- 3 Stocks That Could Put Amazon's Returns to Shame (finance.yahoo.com)
- Vertex Pharmaceuticals (VRTX) a Buy on Solid Sales Growth (investorplace.com)
- Vertex Pharmaceuticals Incorporated (VRTX) Expected to Post Quarterly Sales of $592.47 Million (americanbankingnews.com)
- Vertex Pharmaceuticals (VRTX) and Its Peers Head to Head Survey (americanbankingnews.com)
A number of equities analysts recently issued reports on VRTX shares. Needham & Company LLC reiterated a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a research report on Sunday, September 17th. DA Davidson started coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 29th. They issued a “buy” rating and a $200.00 target price for the company. BTIG Research started coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 29th. They issued a “buy” rating and a $200.00 target price for the company. BMO Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, September 27th. Finally, Vetr lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 target price for the company. in a research report on Monday, September 4th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-three have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $173.15.
Vertex Pharmaceuticals (NASDAQ:VRTX) traded up $0.54 during midday trading on Thursday, hitting $144.29. 1,739,281 shares of the stock were exchanged, compared to its average volume of 1,792,295. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $37,257.64, a price-to-earnings ratio of 245.53, a price-to-earnings-growth ratio of 3.52 and a beta of 1.63. Vertex Pharmaceuticals has a 1-year low of $71.46 and a 1-year high of $167.85.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.49. The business had revenue of $578.20 million during the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The firm’s revenue was up 39.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.16 earnings per share. equities research analysts predict that Vertex Pharmaceuticals will post 0.76 EPS for the current fiscal year.
In related news, EVP Stuart A. Arbuckle sold 4,250 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $148.17, for a total value of $629,722.50. Following the transaction, the executive vice president now owns 46,202 shares in the company, valued at $6,845,750.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Stuart A. Arbuckle sold 6,290 shares of the stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $143.97, for a total value of $905,571.30. Following the completion of the transaction, the executive vice president now owns 116,952 shares in the company, valued at approximately $16,837,579.44. The disclosure for this sale can be found here. Insiders sold 218,519 shares of company stock valued at $31,819,910 over the last three months. 1.80% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: “Vertex Pharmaceuticals (VRTX) Receiving Somewhat Favorable News Coverage, Report Finds” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/11/30/vertex-pharmaceuticals-vrtx-receiving-somewhat-favorable-news-coverage-report-finds.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.